2019 Q3 Form 10-Q Financial Statement
#000119312519209916 Filed on August 01, 2019
Income Statement
| Concept | 2019 Q3 | 2019 Q2 | 2018 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $10.18M | $2.220M | $2.730M |
| YoY Change | 127.23% | -48.49% | -45.07% |
| % of Gross Profit | |||
| Research & Development | $47.72M | $10.00K | $2.570M |
| YoY Change | 345.4% | -99.94% | -77.77% |
| % of Gross Profit | |||
| Depreciation & Amortization | |||
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $59.52M | $428.0K | $5.300M |
| YoY Change | 291.63% | -98.08% | -67.94% |
| Operating Profit | -$59.52M | -$428.0K | |
| YoY Change | 291.63% | -115.91% | |
| Interest Expense | $390.0K | $430.0K | $430.0K |
| YoY Change | -17.02% | 22.86% | 59.26% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $384.0K | $427.0K | -$10.00K |
| YoY Change | 88.24% | 87.28% | |
| Pretax Income | -$59.13M | $0.00 | -$4.890M |
| YoY Change | 294.46% | -100.0% | -69.94% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$59.13M | -$1.000K | -$4.890M |
| YoY Change | 294.4% | -100.03% | -69.94% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$2.258M | $0.00 | -$207.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 23.54M | 23.54M | 23.54M shares |
| Diluted Shares Outstanding | 23.54M |
Balance Sheet
| Concept | 2019 Q3 | 2019 Q2 | 2018 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $66.30M | $72.70M | $76.90M |
| YoY Change | -23.53% | -28.8% | -28.86% |
| Cash & Equivalents | $66.31M | $72.70M | $76.93M |
| Short-Term Investments | $0.00 | ||
| Other Short-Term Assets | |||
| YoY Change | |||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $1.300M | $500.0K | $200.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $67.58M | $73.21M | $77.17M |
| YoY Change | -22.58% | -29.09% | -29.09% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.388M | $318.0K | $400.0K |
| YoY Change | 197.22% | -59.28% | -55.8% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $0.00 | $0.00 | $100.0K |
| YoY Change | -100.0% | -100.0% | -83.33% |
| Total Long-Term Assets | $2.209M | $534.0K | $453.0K |
| YoY Change | 323.99% | -54.94% | -69.88% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $67.58M | $73.21M | $77.17M |
| Total Long-Term Assets | $2.209M | $534.0K | $453.0K |
| Total Assets | $69.79M | $73.74M | $77.62M |
| YoY Change | -20.52% | -29.38% | -29.65% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.300M | $1.000M | $4.600M |
| YoY Change | -78.5% | -92.48% | -58.18% |
| Accrued Expenses | $200.0K | $200.0K | |
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $100.0K | ||
| YoY Change | |||
| Total Short-Term Liabilities | $2.565M | $1.159M | $4.627M |
| YoY Change | -76.14% | -91.32% | -57.77% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $100.0K | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $200.0K | $2.000K | $319.0K |
| YoY Change | -41.69% | -99.5% | -34.36% |
| Total Long-Term Liabilities | $300.0K | $2.000K | $319.0K |
| YoY Change | -12.54% | -99.5% | -34.36% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.565M | $1.159M | $4.627M |
| Total Long-Term Liabilities | $300.0K | $2.000K | $319.0K |
| Total Liabilities | $2.916M | $1.414M | $4.946M |
| YoY Change | -73.71% | -89.72% | -56.77% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$291.4M | -$232.3M | -$230.1M |
| YoY Change | 29.41% | 10.51% | 15.91% |
| Common Stock | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $66.88M | $72.33M | $72.67M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $69.79M | $73.74M | $77.62M |
| YoY Change | -20.52% | -29.38% | -29.65% |
Cashflow Statement
| Concept | 2019 Q3 | 2019 Q2 | 2018 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$59.13M | -$1.000K | -$4.890M |
| YoY Change | 294.4% | -100.03% | -69.94% |
| Depreciation, Depletion And Amortization | |||
| YoY Change | |||
| Cash From Operating Activities | -$6.530M | -$1.470M | -$9.780M |
| YoY Change | -57.57% | -116.01% | -15.76% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$100.0K | $0.00 | $0.00 |
| YoY Change | -600.0% | -100.0% | -100.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $190.0K | $0.00 | $0.00 |
| YoY Change | -93.67% | -100.0% | -100.0% |
| Cash From Investing Activities | $90.00K | $0.00 | $0.00 |
| YoY Change | -97.02% | -100.0% | -100.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 30.00K | 0.000 | 0.000 |
| YoY Change | -250.0% | -100.0% | -100.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -6.530M | -1.470M | -9.780M |
| Cash From Investing Activities | 90.00K | 0.000 | 0.000 |
| Cash From Financing Activities | 30.00K | 0.000 | 0.000 |
| Net Change In Cash | -6.410M | -1.470M | -9.780M |
| YoY Change | -48.26% | -104.52% | -298.78% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$6.530M | -$1.470M | -$9.780M |
| Capital Expenditures | -$100.0K | $0.00 | $0.00 |
| Free Cash Flow | -$6.430M | -$1.470M | -$9.780M |
| YoY Change | -58.27% | -115.96% | -15.69% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4627000 | |
| CY2019Q2 | us-gaap |
Lease Cost
LeaseCost
|
73000 | |
| CY2019Q2 | us-gaap |
Assets
Assets
|
73743000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
400000 | |
| CY2019Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
186000 | |
| CY2019Q2 | aqxp |
Prepayments And Deposits Noncurrent
PrepaymentsAndDepositsNoncurrent
|
30000 | |
| CY2018Q4 | aqxp |
Prepayments And Deposits Noncurrent
PrepaymentsAndDepositsNoncurrent
|
53000 | |
| CY2019Q2 | aqxp |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
509000 | |
| CY2018Q4 | aqxp |
Receivables Prepayments And Deposits Current
ReceivablesPrepaymentsAndDepositsCurrent
|
237000 | |
| CY2019Q2 | us-gaap |
Assets Current
AssetsCurrent
|
73209000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
77165000 | |
| CY2019Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
318000 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
96000 | ||
| CY2019Q2 | us-gaap |
Liabilities
Liabilities
|
1414000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
4946000 | |
| CY2019Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
||
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
||
| CY2018Q4 | us-gaap |
Assets
Assets
|
77618000 | |
| CY2019Q2 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
958000 | |
| CY2018Q4 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
4627000 | |
| CY2019Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
304625000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
302759000 | |
| CY2019Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-232296000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-230087000 | |
| CY2019Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1159000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72329000 | |
| CY2019Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
73743000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
77618000 | |
| CY2019Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23537368 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23537368 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23537368 | |
| CY2019Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23537368 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Nature of operations </div></div></div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"> </div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;">Aquinox Pharmaceuticals, Inc. and its subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated, the “Company”) is a pharmaceutical company discovering and developing novel therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers.</div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"> </div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;">In June 2018, the Company announced that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint. As a result, all further development activities with rosiptor were halted. In July 2018, the Company announced a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business. In November 2018, the Company’s Board of Directors approved further restructuring to reduce operating costs. As of the date of this report, the Company does not have any product candidates in clinical development or identified for clinical development. The Company is currently evaluating strategic options.</div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"> </div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;">Aquinox Pharmaceuticals, Inc. was originally incorporated under the name of Aquinox Pharmaceuticals (USA) Inc. on <div style="letter-spacing: 0px; top: 0px;;display:inline;">May 31, 2007</div> in the State of Delaware, United States. On January 27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (“Aquinox USA”).</div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;"> </div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;">Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”) was originally incorporated under the name of 6175813 Canada Inc. on <div style="letter-spacing: 0px; top: 0px;;display:inline;">December 26, 2003</div> under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; padding-top: 0pt; padding-bottom: 0pt; line-height: 12pt;">The Company operates in Vancouver, British Columbia, Canada.</div> <div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 18pt; line-height: 12pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">(b) Use of estimates and assumptions </div></div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 6pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates include valuation of stock options, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3087000 | ||
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
25000000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
25000000 | ||
| CY2019Q2 | aqxp |
Research And Development Expense Net Of Restructuring Recoveries
ResearchAndDevelopmentExpenseNetOfRestructuringRecoveries
|
-1995000 | |
| CY2018Q2 | aqxp |
Research And Development Expense Net Of Restructuring Recoveries
ResearchAndDevelopmentExpenseNetOfRestructuringRecoveries
|
17996000 | |
| aqxp |
Research And Development Expense Net Of Restructuring Recoveries
ResearchAndDevelopmentExpenseNetOfRestructuringRecoveries
|
-1891000 | ||
| aqxp |
Research And Development Expense Net Of Restructuring Recoveries
ResearchAndDevelopmentExpenseNetOfRestructuringRecoveries
|
28504000 | ||
| CY2019Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2423000 | |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4314000 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4978000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8623000 | ||
| CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
428000 | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
22310000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
3087000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
37127000 | ||
| CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-428000 | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
2690000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12127000 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.12 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.09 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.50 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.12 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.09 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.50 | ||
| CY2019Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23537368 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23521719 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23537368 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23501351 | ||
| CY2019Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23537368 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23846256 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23537368 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23501351 | ||
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1000 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
2918000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-2209000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-11705000 | ||
| CY2018Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
22000 | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
68000 | ||
| CY2019Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1000 | |
| CY2018Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
2940000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2209000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11637000 | ||
| CY2019Q2 | us-gaap |
Cash
Cash
|
23032000 | |
| CY2018Q4 | us-gaap |
Cash
Cash
|
25061000 | |
| CY2018Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
6000 | |
| CY2019Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
49668000 | |
| CY2018Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
51867000 | |
| CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
72700000 | |
| us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
4000 | ||
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
76928000 | |
| CY2019Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
2000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
313000 | |
| CY2019Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
319000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-2209000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-11705000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1866000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2825000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-155000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-322000 | ||
| aqxp |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
246000 | ||
| aqxp |
Increase Decrease In Receivables Prepayments And Deposits
IncreaseDecreaseInReceivablesPrepaymentsAndDeposits
|
174000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
-3792000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
2324000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4226000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6408000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
53000000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
69000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
52931000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
602000 | ||
| us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
8000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-4000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
594000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-19000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-4228000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
47098000 | ||
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
76928000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
52032000 | |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
72700000 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
99130000 | |
| us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
880000 | ||
| us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
736000 | ||
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
71542000 | |
| CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
788000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
85825000 | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
399000 | |
| CY2018Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1513000 | |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
90677000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72672000 | |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1866000 | ||
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
98887000 | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
602000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2825000 | ||
| CY2019Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
31000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
62000 | ||
| CY2019Q2 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
42000 | |
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
90000 | ||
| us-gaap |
Lease Cost
LeaseCost
|
152000 | ||
| CY2019Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
55000 | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
515000 | ||
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
|
206000 | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
|
209000 | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
|
70000 | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
485000 | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
31000 | |
| CY2019Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
454000 | |
| CY2019Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
201000 | |
| CY2019Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
253000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
362000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
336000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
280000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
978000 | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.06 | |
| CY2019Q2 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
200000 | |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
400000 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
0 | ||
| CY2018 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
0 | |
| CY2019Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2631097 | |
| CY2018Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
324537 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2744109 | ||
| CY2019Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
436000 | |
| CY2018Q2 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
376000 | |
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
886000 | ||
| us-gaap |
Investment Income Net
InvestmentIncomeNet
|
624000 | ||
| CY2019Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-9000 | |
| CY2018Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-30000 | |
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-7000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-31000 | ||
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-118000 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-171000 | ||
| CY2019Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
427000 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
878000 | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0 | ||
| CY2018Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
228000 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
422000 | ||
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
| CY2018 | aqxp |
License And Collaboration Agreement Terms
LicenseAndCollaborationAgreementTerms
|
The license and collaboration agreement also included an upfront payment of $25.0 million and contractual milestones. | |
| CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
25000000 | |
| CY2018 | aqxp |
Non Refundable Up Front Payment Received
NonRefundableUpFrontPaymentReceived
|
25000000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2897294 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.04 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y11M15D | |
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0282 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
266197 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
11.76 | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2631097 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.76 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y7M6D | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1160663 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
11.58 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y3D | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.86 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.77 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0274 | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
9.60 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.83 | ||
| aqxp |
Common Stock Reserved For Issuance Description
CommonStockReservedForIssuanceDescription
|
Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. | ||
| CY2019Q2 | aqxp |
Stock Shares Authorized Net
StockSharesAuthorizedNet
|
55000000 | |
| CY2019Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
| CY2019Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2019Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
4725551 | |
| aqxp |
Stock Based Compensation Increase In Common Stock Issuance Percentage
StockBasedCompensationIncreaseInCommonStockIssuancePercentage
|
0.04 | ||
| aqxp |
Period Shares Reserved For Issuance Will Increase
PeriodSharesReservedForIssuanceWillIncrease
|
P10Y | ||
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y5M1D | ||
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y | ||
| CY2019Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
800000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1900000 | ||
| CY2018Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1500000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2800000 | ||
| CY2019Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
5900000 | |
| CY2018Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
15400000 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | ||
| dei |
Trading Symbol
TradingSymbol
|
AQXP | ||
| CY2019Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
23537368 | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2019-06-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2019 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
AQUINOX PHARMACEUTICALS, INC | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001404644 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
| dei |
Security12b Title
Security12bTitle
|
Common Stock | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
DE | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2631097 | ||
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2007-05-31 | ||
| CY2019Q2 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
| dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | ||
| dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
| CY2019Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 |
